Trial Profile
A Phase II Trial of Pembrolizumab Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Jan 2024 Status changed from active, no longer recruiting to completed.
- 26 Apr 2023 Planned End Date changed from 1 Jan 2023 to 1 Dec 2024.
- 26 Apr 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Dec 2023.